Tyr354
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr354  -  Ezrin (mouse)

Site Information
LMLRLQDyEQKTKRA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448105

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 7 )
Disease tissue studied:
leukemia ( 7 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 7 )
Relevant cell line - cell type - tissue:
B lymphocyte ( 4 )

Upstream Regulation
Putative upstream phosphatases:
PTPRS (mouse) ( 1 )
Phosphatases, in vitro:
PTPRS (human) ( 1 )

Downstream Regulation
Effects of modification on Ezrin:
intracellular localization ( 1 )
Effects of modification on biological processes:
apoptosis, inhibited ( 7 ) , cell growth, altered ( 7 )

References 

1

Murchie R, et al. (2014) Protein tyrosine phosphatase σ targets apical junction complex proteins in the intestine and regulates epithelial permeability. Proc Natl Acad Sci U S A 111, 693-8
24385580   Curated Info

2

Ren H (2011) CST Curation Set: 12902; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Ren H (2011) CST Curation Set: 12904; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Ren H (2011) CST Curation Set: 12894; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Ren H (2011) CST Curation Set: 12895; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Ren H (2011) CST Curation Set: 12900; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Monni R, et al. (2008) Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. Blood 111, 3163-72
18182570   Curated Info